Drug and Therapeutics Bulletin 2001;39:89-91; doi:10.1136/dtb.2001.391289
Copyright © 2001 by the BMJ Publishing Group Ltd.
Is 
sibutramine more than a slim hope?
Relevant BNF section: 4.5.2
▼Sibutramine* (Reductil - Abbott Laboratories), an orally active monoamine re-uptake inhibitor, is marketed in the UK for treating overweight adults. The company claims that it "helps obese patients control their eating". Is the drug worth prescribing?
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
-
(2008). Surgery for obesity in adults. DTB
46: 41-45
[Abstract] [Full Text] -
Richards, R.
(2002). Rehabilitation services remain important in multiple sclerosis. BMJ
324: 977-977
[Full Text]
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with
Register for email alerts
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
Coming soon!
The DTB archive back to 1962, volume 1, issue 1 will soon be available.
